EGb 761 in the Syndrome of MCI With Concomitant CVD
EGb 761 in the Syndrome of MCI With Concomitant CVD
The study aims to determine the efficacy and safety profile of EGb 761 as a prescribed
 clinical drug for patients with MCI + CVD. This study is an open label 52-weeks study in
 subjects who have both MCI (based on the Petersen criteria and Albert MS criteria) and CVD.
 Eligibility for enrolment will be assessed initially at a screening visit, which is to occur
 within 42 days of baseline. 134 male and female subjects will participate and 67 of the 134
 will receive the drug. Subjects will be randomized to the EGB 761 arm and control arm in a
 1:1 ratio using a block randomization method in groups of 4 subjects using an automated
 randomization software.

 EGb 761 has been demonstrated to be useful in improving cognitive and global clinical
 outcomes in patients with cognitive impairment or dementia, when administered at a daily
 dosage of 240mg in randomised controlled trials through several neuroprotective mechanisms of
 action. The study will allow generating data in an Asian and multi-racial population and
 allows physicians to offer clinically efficacious and alternative treatment for patients with
 MCI + CVD.
Inclusion Criteria:

 -  Patients who have been diagnosed with MCI based on the Petersen criteria and Albert MS
 criteria

 -  Patients who have a Global Clinical Dementia Rating Score of 0.5

 -  Patients aged 45 to 85 years at study entry

 -  Patients who are literate and able to complete the cognitive evaluations in the
 opinion of the investigators

 -  Patients with the presence of CVD, defined as the presence of white matter
 hyperintensities (WMH) of Fazekas grade 2 or 3 on MRI brain imaging (done up to 12
 months prior to recruitment) or CT scans for patients contraindicated from MRI scans

 -  Patients who provide written informed consent to participate in the study

 Exclusion Criteria:

 -  Participants should not be receiving antidepressants, antipsychotics, benzodiazepines,
 acetylcholinesterase inhibitors or NMDA antagonists during the study. Additionally,
 contraindications for EGb 761 as given in the local prescribing information/Summary of
 Product Characteristics (SmPC) should be observed.